Axial Spondyloarthritis (AxSpA)
Symptoms, Doctors, Treatments, Advances & More

Axial Spondyloarthritis (AxSpA) Overview

Save information for later
Sign Up

Learn About Axial Spondyloarthritis (AxSpA)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Axial Spondyloarthritis (AxSpA) Local Doctors?
Elite in Axial Spondyloarthritis (AxSpA)
Dr. Philip J. Mease
Rheumatology
Elite in Axial Spondyloarthritis (AxSpA)
Dr. Philip J. Mease
Rheumatology

Seattle Rheumatology Associates

601 Broadway, 
Seattle, WA 
206-386-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Mease graduated from Stanford University receiving his Medical Doctorate. He specializes in internal medicine and rheumatology. Dr. Mease is a practicing physician at Seattle Rheumatology Associates, Swedish Cherry Hill, and Swedish First Hill. Dr. Mease is rated as an Elite provider by MediFind in the treatment of Axial Spondyloarthritis (AxSpA). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Arthritis, Psoriasis, and Axial Spondyloarthritis (AxSpA). Dr. Mease is board certified in American Board Of Internal Medicine. Dr. Mease is currently accepting new patients.

Elite in Axial Spondyloarthritis (AxSpA)
Denis A. Poddubnyy
Elite in Axial Spondyloarthritis (AxSpA)
Denis A. Poddubnyy

Infectiology And Rheumatology

Berlin, BE, DE 

Denis Poddubnyy practices practicing medicine in Berlin, Germany. Mr. Poddubnyy is rated as an Elite expert by MediFind in the treatment of Axial Spondyloarthritis (AxSpA). He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Axial Spondyloarthritis (AxSpA), Ankylosing Spondylitis, Arthritis, and Psoriatic Arthritis.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Axial Spondyloarthritis (AxSpA)
Joachim Sieper
Elite in Axial Spondyloarthritis (AxSpA)
Joachim Sieper
Berlin, BE, DE 

Joachim Sieper practices practicing medicine in Berlin, Germany. Mr. Sieper is rated as an Elite expert by MediFind in the treatment of Axial Spondyloarthritis (AxSpA). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Arthritis, and Necrosis.

View All Doctors
What are the latest Axial Spondyloarthritis (AxSpA) Clinical Trials?
A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis
A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \[ERAP1\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

View All Clinical Trials